Dry Eye Disease Therapies at a Crossroads—A Call for Reform

IF 10.5 1区医学 Q1 OPHTHALMOLOGY

JAMA ophthalmology Pub Date : 2026-09-17 DOI:10.1001/jamaophthalmol.2026.3983

Esen K. Akpek, Meron Haile, John Gonzales, Sandeep Jain

引用次数: 0

Abstract

This Viewpoint discusses current approval pathways for dry eye disease medications and the need to advance the standard of evidence for these medications.

查看原文本刊更多论文

干眼病治疗处于十字路口——呼吁改革

本观点讨论了目前干眼病药物的批准途径以及提高这些药物的证据标准的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JAMA ophthalmology OPHTHALMOLOGY-

CiteScore

13.20

自引率

3.70%

发文量

340

期刊介绍： JAMA Ophthalmology, with a rich history of continuous publication since 1869, stands as a distinguished international, peer-reviewed journal dedicated to ophthalmology and visual science. In 2019, the journal proudly commemorated 150 years of uninterrupted service to the field. As a member of the esteemed JAMA Network, a consortium renowned for its peer-reviewed general medical and specialty publications, JAMA Ophthalmology upholds the highest standards of excellence in disseminating cutting-edge research and insights. Join us in celebrating our legacy and advancing the frontiers of ophthalmology and visual science.